Literature DB >> 11253113

Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.

H Maeta1, S Ohgi, T Terada.   

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play an important role in tumor invasion and metastasis. There have been only a few studies on the protein expression of MMPs and TIMPs in thyroid carcinomas. Therefore, we investigated the protein expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 in 86 papillary thyroid carcinomas using immunohistochemistry, semiquantitative scoring morphometry of immunohistochemistry, gelatin zymography, and western blotting. We also examined the correlations between the immunohistochemical scores and several clinicopathological parameters. The immunoreactivities of MMP-2, MMP-9, TIMP-1, and TIMP-2 were largely located in the tumor cells or non-tumor follicular cells and to a much lesser extent in the fibroblasts and endothelial cells in the tumor and non-tumor regions. Compared with non-tumor regions, these four proteins tended to be overexpressed in the tumor cells; the overexpression was found in 64 of 86 (74%), 80 of 86 (93%), 79 of 86 (92%), and 64 of 86 (74%) cases for MMP-2, MMP-9, TIMP-1, and TIMP-2, respectively. Gelatin zymography showed distinct bands of MMP-2 and MMP-9 in tumor extracts but vague bands in non-tumor extracts. Western blotting revealed the specific bands of MMP-2 and MMP-9 in both tumor and non-tumor extracts. Morphometric scoring revealed that high expression of these proteins significantly correlated with large tumor size, presence of lymph node metastasis, high clinical stage, high intrathyroidal invasion, and high vascular invasion. These data suggest that MMP-2, MMP-9, TIMP-1, and TIMP-2 proteins and activities are increased in tumors cells of papillary thyroid carcinomas and that they play an important role in the invasion and metastasis of papillary thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253113     DOI: 10.1007/s004280000286

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Ni Wang; Rong Jiang; Jun-Yan Yang; Cui Tang; Lei Yang; Man Xu; Qi-Feng Jiang; Zhi-Min Liu
Journal:  J Mol Histol       Date:  2013-11-26       Impact factor: 2.611

2.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Po-Sheng Yang; Ming-Nan Chien; Yuan-Ching Chang; Chi-Hsin Lin; Shih-Ping Cheng
Journal:  Histochem Cell Biol       Date:  2018-03-12       Impact factor: 4.304

4.  Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.

Authors:  Szu-Tah Chen; Dah-Wel Liu; Jen-Der Lin; Fang-Wu Chen; Yu-Yao Huang; Brend Ray-Sea Hsu
Journal:  Clin Exp Metastasis       Date:  2011-11-01       Impact factor: 5.150

5.  Expression of MMP-2 and MMP-9 in retinoblastoma and their significance.

Authors:  Hua Long; Bo Zhou; Fa-Gang Jiang
Journal:  Int J Ophthalmol       Date:  2011-10-18       Impact factor: 1.779

Review 6.  Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Lei Chen; Hong-Yu Zhang
Journal:  Molecules       Date:  2007-05-03       Impact factor: 4.411

7.  Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Janelle M Ortiz; Terry C Lairmore; Nicholas S Duesbery; Ian C Mitchell; Fiemu Nwariaku; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  The association of matrix metalloproteinase-1 genetic polymorphism (-1607 1G>2G) with colorectal cancer: a meta-analysis.

Authors:  Shu-Rong Ji; Jian-Jun Sun; Xin-Ping Li; Yi Zhang; Wen-Fang Liu
Journal:  Tumour Biol       Date:  2013-07-20

9.  In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.

Authors:  Marius I Ilie; Sandra Lassalle; Elodie Long-Mira; Véronique Hofman; Joséphine Zangari; Gilles Bénaim; Alexandre Bozec; Nicolas Guevara; Juliette Haudebourg; Isabelle Birtwisle-Peyrottes; José Santini; Patrick Brest; Paul Hofman
Journal:  Virchows Arch       Date:  2013-07-27       Impact factor: 4.064

10.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.

Authors:  Charlotte Aaberg-Jessen; Karina Christensen; Hanne Offenberg; Annette Bartels; Tanja Dreehsen; Steinbjørn Hansen; Henrik Daa Schrøder; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.